

REFERENCES

- Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. *Nat Rev Immunol*. 2010;10(6):440-52.
- Adiletta S, Candiello A, Arminio D, Porcaro S, Saporito G, Palomba R. Sinergismo tra pregabalin e palmitoiletanolamide (PEA) nel trattamento della neuropatia diabetica. 34° Congresso nazionale AISD Riccione 29-31 maggio 2011
- Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. *Agents Actions*. 1993;39 Spec No:C145-7.
- Anand P, Singh B, Jaggi AS, Singh N. Mast cells: an expanding pathophysiological role from allergy to other disorders Naunyn Schmiedebergs Arch Pharmacol. 2012;385(7):657-70.
- Assini A., Laricchia D., Bellotti M., Pandolfini L., Pizzo R., Ratto S. The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide. 2010 EFNS European Journal of Neurology 17 (Suppl. 3)
- Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. *CNS Neurol Disord Drug Targets*. 2013;12(1):34-44.
- Biasiotta A, Di Stefano G, Leone C, La Cesa S, Truini A, Cruccu G. Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clinical and neurophysiological open study. Preliminary results. NeuPSIG 2010 - 3rd International Congress on Neuropathic Pain. 2010, Athens (Grecia)
- Bulanova E, Bultone-Paus S. P2 receptor-mediated signaling in mast cell biology *Purinergic Signal*. 2010;6(1):3-17.
- Calabrò RS, Bramanti P. Occipital Neuralgia Responding to Palmitoylethanolamide Headache. 2013.
- Canteri L, Petrosino S, Guida G. Reducción del consumo de antiinflamatorios y analgésicos en el tratamiento del dolor neuropático crónico en pacientes afectados por lumbociatalgia de tipo compresivo y en tratamiento con normast® 300 mg. *Dolor* 2010; 25(4):227-34
- Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. *Vet Immunol Immunopathol*. 2010;133(1):9-15.
- Conigliaro R, Drago V, Foster PS., Schievano C, Di Marzo V. Use of the Palmitoylethanolamide in the Entrapment Neuropathy of the Median in the Wrist. *Minerva Medica*. 2011; 102(2):141-7.
- Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabixone in a model of acute inflammation in the rat. *Br J Pharmacol*. 2002 ;135(1):181-7.
- Costa B, Colombo A, Bettoni I, Bresciani E, Torsello A, Comelli F. The endogenous ligand palmitoylethanolamide relieves neuropathic pain via mast cell and microglia modulation. The 21st Annual Symposium of the International Cannabinoid Research Society. Jul. 06, 2011 - Jul 09, 2011 Chicago.
- Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. *Pain*. 2008;139(3):541-50.
- Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. *Br J Pharmacol*. 2002 Oct;137(4):413-20.
- Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algül H, Friess H, Ceyhan GO. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. *PLoS One*. 2013;8(3):e60529.
- Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M. Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism. *Mediators of Inflammation* Volume 2013; 2013:328797.
- Dominguez CM, Martín A, Ferrer FG, Puertas MAI, Muro AL, González JCM, Prieto JP, Taberna IR. N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica *Pain Manage.* (2012) 2(2), 119–124
- Esposito E, Paterniti I, Mazzoni E, Genovese T, Di Paola R, Galuppo B, Cuzzocrea S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. *Brain Behav Immun*. 2011 Aug;25(6):1099-112.
- Forsythe P, Bienenstock J. The mast cell-nerve functional unit: a key component of physiologic and pathophysiological responses. *Chem Immunol Allergy*. 2012;98:196-221.
- Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogeneses. *Pain Med*. 2012; 13(9):1121-30.
- Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerde B. Palmitoylethanolamide and stearyl ethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. *Pain*. 2013, [in press].
- Gianfelice V, Lazzari M, Finocchi S, Frasca MG, Palombo E, Bellucci O, Luciani S, Guantera D, Divizia M, Gatti A. Palmitoiletanolamide nel trattamento del dolore cronico associato a differenti eziopatogenesi 36° Congresso Nazionale Associazione Italiana Associazione Italiana Verona, 30 maggio-1° giugno 2013
- Granberg M, Fowler CJ, Jacobsson SO. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2H3 basophilic leukaemic cells. *Naunyn Schmiedebergs Arch Pharmacol*. 2001 ;364(1):66-73.
- Guida G, de Fabiani A, Lanaia F, Alexandre A, Vassallo GM, Cantieri L, de Martino M, Rogai M, Petrosino S. La palmitoiletanolamide (normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. *Dolor*. 2010; 25:35-42
- Jack DB. Alkylamides: a new approach to the treatment of inflammation. *DN&P*; 1996; 9(2):93-98
- Kim DY, Hong GU, Ro JY. Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. *J Neuroinflammation*. 2011;8:25.
- Kim DY, Jeoung D, Ro JY. Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. *J Immunol*. 2010;185(1):273-83.
- Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokin. *Trends Neurosci*. 1996;19(11):514-20.
- Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. *Anesthesiology*. 2012 Apr;116(4):882-95.
- Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. *Cell Mol Life Sci*. 2011;68(6):965-75.
- Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. *CNS Neurol Disord Drug Targets*. 2013;
- Luongo L, Palazzo E, de Novellis V, Maione S. Role of Endocannabinoids in Neuron-Glial Crosstalk. *The Open Pain Journal*. 2010, 3, 29-36.
- Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. *J Orofac Pain*. 2012 Spring;26(2):99-104.
- Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. *Eur J Pharmacol*. 1996;300(3):227-36.
- Medic N, Lorenzon P, Vita F, Trevisan E, Marchioli A, Soranzo MR, Fabbretti E, Zucchi G. Mast cell adhesion induces cytoskeletal modifications and programmed cell death in oligodendrocytes. *J Neuroimmunol*. 2010 ;218(1-2):57-66.
- Mizisin AP, Weerasuriya A. Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. *Acta Neuropathol*. 2011;121(3):291-312.
- Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? *Mol Interv*. 2007;7(1):26-41.
- Palomba R, Adiletta S, Candiello A, Pennimpede M, Bonaccia P, De Martino CJ. Multimodal analgesia for chronic pain: rationale and future directions. Naples Pain Conference (NPC): Research and Therapy for human and animal suffering MAY 16 - 19 , 2010
- Parabita M, D'Amore RM, Marinucci F, Matera MG, Izzo A, Russo GA Reduction of post stroke spasticity with Palmitoylethanolamide treatment. XIV Congress of the European Shock Society. 2011. Taormina, August 31, September 2.
- Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S. Molecular evidence for the involvement of PPAR- α and PPAR- β in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. *J Neuroinflammation*. 2013 Feb 1;10:20.
- Ren K, Dubner R. Interactions between the immune and nervous systems in pain. *Nat Med*. 2010;16(11):1267-76.
- Rosa AC, Fantozzi R. Histamine in the neurogenic inflammation. *Br J Pharmacol*. 2013;
- Rozniecki JJ, Dimitriadou V, Lambricht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. *Brain Res*. 1999;4;849(1-2):1-15.
- Schiffilliti C., Cucinotta L., Fedele V., Ingegnosi C., Luca S., Leotta C. Palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. *Panminerva Med.* (submitted) 2013
- Skaper SD, Facci L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. *Philos Trans R Soc Lond B Biol Sci*. 2012 Dec 5;367(1607):3312-25. Review.
- Skaper SD, Giusti P, Facci L. Microglia and mast cells: two tracks on the road to neuroinflammation. *FASEB J*. 2012 Aug;26(8):3103-17. Review.
- Szpak GM, Lewandowska E, Lechowicz W, Wierzbobrowicz T, Kulczycki J, Bertrand E, Pasennik E, Dymecki J. The brain immune response in human prion diseases. Microglial activation and microglial disease. I. Sporadic Creutzfeldt-Jakob disease. *Folia Neuropathol*. 2006;44(3):202-13.
- Truini A, Biasiotta A, Di Stefano G, Cesa SL, Leone C, Carboni C, Federico V, Petrucci MT, Cruccu G. Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy. *CNS Neurol Disord Drug Targets*. 2011;10(8):916-20.
- Wise LE, Cannavacciuolo R, Cravatt BF, Martin BF, Lichtman AH. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. *Neuropharmacology*. 2008;54(1):181-8.
- Yuan H, Zhu X, Zhou S, Chen Q, Zhu X, Ma X, He X, Tian M, Shi X. Role of mast cell activation in inducing microglial cells to release neurotrophin. *J Neurosci Res*. 2010;88(6):1348-54.
- Zhang F, Vadakkan KI, Kim SS, Wu LJ, Shang Y, Zhuo M. Selective activation of microglia in spinal cord but not higher cortical regions following nerve injury in adult mouse. *Mol Pain*. 2008;18:4:15.
- Zheng FY, Xiao WH, Bennett GJ. The response of spinal microglia to chemotherapy-evoked painful peripheral neuropathies is distinct from that evoked by traumatic nerve injuries. *Neuroscience*. 2011;176:447-54.